CN110575446A - compound inhalation composition and preparation method thereof - Google Patents
compound inhalation composition and preparation method thereof Download PDFInfo
- Publication number
- CN110575446A CN110575446A CN201910845879.2A CN201910845879A CN110575446A CN 110575446 A CN110575446 A CN 110575446A CN 201910845879 A CN201910845879 A CN 201910845879A CN 110575446 A CN110575446 A CN 110575446A
- Authority
- CN
- China
- Prior art keywords
- conveying
- solution
- budesonide
- ambroxol hydrochloride
- inhalation composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a preparation method of a compound inhalation composition, which comprises the following steps: s1, conveying the budesonide solution through a first conveying component; s2, conveying the ambroxol hydrochloride solution through a second conveying component, and mixing the ambroxol hydrochloride solution and the budesonide solution to form a mixed solution; and S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition. Also relates to a compound inhalation composition. The compound composition has the advantages that the concentration and the flow of the budesonide solution and the ambroxol hydrochloride solution are adjusted, so that the proportion of the two components in the compound composition is adjusted, the two active components are dissolved out at the same speed, and the effect of releasing at the same proportion is achieved; the compound composition is applied to a male New Zealand white rabbit pneumonia model, can obtain an excellent anti-inflammatory effect, and plays a role in inhibiting mucus.
Description
Technical Field
The invention relates to the technical field of preparation of pneumonia anti-inflammatory preparations, in particular to a compound inhalation composition and a preparation method thereof.
background
budesonide is a glucocorticoid with high-efficiency local anti-inflammatory action, and can enhance the stability of endothelial cells, smooth muscle cells and lysosome membranes, inhibit immune reaction, reduce antibody synthesis, reduce the release of allergic active mediators such as histamine and the like and the activity of the allergic active mediators, relieve the enzymatic process stimulated when antigen-antibody is combined, inhibit the synthesis and release of bronchoconstrictor substances and relieve the contraction reaction of smooth muscles. Therefore, it is generally used for treating patients with glucocorticoid-dependent or independent bronchial asthma and asthmatic chronic bronchitis in clinic.
Ambroxol hydrochloride is a phlegm-eliminating compound, can dissolve secretion, has the effect of promoting mucus elimination, can promote the discharge of mucus in respiratory tract, reduces the detention of mucus, can obviously promote sputum elimination, and improves the respiratory condition.
Therefore, a compound composition of the budesonide and the ambroxol hydrochloride is needed to improve the treatment effect of the pneumonia.
Disclosure of Invention
The invention aims to provide a compound inhalation composition and a preparation method thereof aiming at the defects in the prior art.
In a first aspect of the present invention, there is provided a method for preparing a combination inhalation composition, comprising:
S1, conveying the budesonide solution through a first conveying component;
S2, conveying the ambroxol hydrochloride solution through a second conveying component, and mixing the ambroxol hydrochloride solution and the budesonide solution to form a mixed solution;
S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition;
Wherein the conveying speed of the first conveying component is V1, the conveying speed of the second conveying component is V2, and the units of V1 and V2 are ml/min;
The concentration of the budesonide solution is C1, the concentration of the ambroxol hydrochloride solution is C2, and the units of C1 and C2 are g/ml;
wherein V1 is different from V2, and C1 is different from C2.
Preferably, the first transport component, the second transport component and the third transport component are integrated in a spray head device.
preferably, the conveying speed V1 of the first conveying member is greater than the conveying speed V2 of the second conveying member;
the concentration C1 of the budesonide solution is less than the concentration C2 of the ambroxol hydrochloride solution.
preferably, the conveying speed V1 of the first conveying member is lower than the conveying speed V2 of the second conveying member;
The concentration C1 of the budesonide solution is greater than the concentration C2 of the ambroxol hydrochloride solution.
Preferably, the product of the conveying speed V1 of the first conveying part and the concentration C1 of the budesonide solution is V3, the product of the conveying speed V2 of the second conveying part and the concentration C2 of the ambroxol hydrochloride solution is V4, and the units of V3 and V4 are g/min;
wherein V3 is the same as V4.
Preferably, V3 is 1 g/ml;
V4 was 1 g/ml.
Preferably, the conveying speed of the third conveying component is 160-330m3/h。
Preferably, the temperature of the drying gas is 60-100 ℃.
another object of the present invention is to provide a composite inhalation composition prepared by the above method, wherein the composite inhalation composition comprises budesonide and ambroxol hydrochloride.
Preferably, the weight percentage of the budesonide is greater than the weight percentage of the ambroxol hydrochloride.
preferably, the weight percentage of the budesonide is equal to the weight percentage of the ambroxol hydrochloride.
Preferably, the weight percentage of the budesonide is less than the weight percentage of the ambroxol hydrochloride.
preferably, the composition comprises the following weight percentages:
Budesonide 50-99%
1-50% of ambroxol hydrochloride.
Preferably, the composition comprises the following weight percentages:
budesonide 1-50%
50-99% of ambroxol hydrochloride.
by adopting the technical scheme, compared with the prior art, the invention has the following technical effects:
according to the compound inhalation composition and the preparation method thereof, the concentration and the flow of the budesonide solution and the ambroxol hydrochloride solution are adjusted, so that the proportion of the two components in the compound inhalation composition is adjusted, the two active components are dissolved at the same speed, and the effect of releasing at the same proportion is achieved; the compound composition is applied to a male New Zealand white rabbit pneumonia model, can obtain an excellent anti-inflammatory effect, and plays a role in inhibiting mucus.
Drawings
Fig. 1 is a schematic view of a head unit according to an exemplary embodiment of the present invention.
FIG. 2 is the dissolution profile of example 2.
FIG. 3 is the dissolution profile of example 3.
FIG. 4 is the dissolution profile of example 4.
FIG. 5 is the dissolution profile of example 5.
Wherein the reference numerals are used; a showerhead arrangement 100; a first conveyance member 101; a second conveyance member 102; and a third conveyance member 103.
Detailed Description
the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict.
The invention is further described with reference to the following drawings and specific examples, which are not intended to be limiting.
example 1
In one illustrative embodiment of the present invention, a method of preparing a combination inhalation composition comprises:
S1, conveying the budesonide solution through a first conveying component;
S2, conveying the ambroxol hydrochloride solution through a second conveying component to mix the ambroxol hydrochloride solution and the budesonide solution to form a mixed solution;
And S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition.
wherein the conveying speed of the first conveying component is V1, the conveying speed of the second conveying component is V2, and the unit of V1 and V2 is ml/min;
The concentration of the budesonide solution is C1, the concentration of the ambroxol hydrochloride solution is C2, and the units of C1 and C2 are g/ml;
Wherein V1 is different from V2, and C1 is different from C2.
Wherein the budesonide solution is a budesonide ethanol solution with 1% solid concentration, and the ambroxol hydrochloride solution is an ambroxol hydrochloride aqueous solution with 1% solid concentration.
Further, the first conveying member, the second conveying member and the third conveying member are integrated in a head device.
as shown in fig. 1, the head apparatus 100 includes a first conveying member 101, a second conveying member 102, and a third conveying member 103, wherein the second conveying member 102 is located at a middle portion of the head apparatus 100, and the first conveying member 101 and the third conveying member 103 are respectively disposed at left and right sides of the second conveying member 102.
Further, the second conveying member 102 is linear, and the first conveying member 101 and the third conveying member 103 are zigzag, wherein the first end of the first conveying member 101, the first end of the second conveying member 102, and the first end of the third conveying member 103 are not in contact with each other, and the second end of the first conveying member 101, the second end of the second conveying member 102, and the second end of the third conveying member 103 are in contact with each other.
further, the conveying speed V1 of the first conveying member 101 is greater than the conveying speed V2 of the second conveying member 102, and the concentration C1 of the budesonide solution is less than the concentration C2 of the ambroxol hydrochloride solution.
Further, the conveying speed V1 of the first conveying member 101 is less than the conveying speed V2 of the second conveying member 102, and the concentration C1 of the budesonide solution is greater than the concentration C2 of the ambroxol hydrochloride solution.
Preferably, the product of the conveying speed V1 of the first conveying part 101 and the concentration C1 of the budesonide solution is V3, the product of the conveying speed V2 of the second conveying part 102 and the concentration C2 of the ambroxol hydrochloride solution is V4, and the units of V3 and V4 are g/min;
Wherein V3 is the same as V4.
preferably, V3 is 1g/min and V4 is 1 g/min.
further, the conveying speed of the third conveying component 103 is 160-330m3h, and the temperature of the conveyed drying gas is 60-100 ℃.
Further, the drying rate of the drying gas conveyed by the third conveying part 103 for drying the budesonide solution and the ambroxol hydrochloride solution is 400-1000L/h.
the active ingredients of the compound inhalation composition prepared by the preparation method are budesonide and ambroxol hydrochloride.
Further, the weight percentage of the budesonide is larger than that of the ambroxol hydrochloride.
Further, the weight percentage of budesonide is equal to the weight percentage of ambroxol hydrochloride in terms of weight percentage.
further, the weight percentage of budesonide is less than the weight percentage of ambroxol hydrochloride in terms of weight percentage.
specifically, the compound inhalation composition comprises the following components in percentage by weight:
Budesonide 1-50%
50-99% of ambroxol hydrochloride.
Or, the compound inhalation composition consists of the following components in percentage by weight:
Budesonide 50-99%
1-50% of ambroxol hydrochloride.
example 2
In one embodiment of the present invention, a method for preparing a compound inhalation composition comprises the following steps:
S1, conveying the 1% solid concentration budesonide ethanol solution through a first conveying component;
S2, conveying the ambroxol hydrochloride aqueous solution with the solid concentration of 1% through a second conveying component, and mixing the ambroxol hydrochloride aqueous solution and the budesonide ethanol solution to form a mixed solution;
And S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition.
the compound inhalation composition exists in the form of particles.
wherein the conveying speed V1 of the first conveying component is 9ml/min, and the conveying speed V2 of the second conveying component is 1 ml/min;
The concentration C1 of the budesonide solution is 0.111g/ml, and the concentration C2 of the ambroxol hydrochloride solution is 1.000 g/ml.
The conveying speed of the third conveying component 103 is 160-330m3H, the temperature of the conveyed drying gas is 60-100 ℃, and the drying gas conveyed by the third conveying part 103 dries the budesonide ethanol solutionThe drying rate of the solution and the aqueous solution of ambroxol hydrochloride is 400L/h.
example 3
In one embodiment of the present invention, a method for preparing a compound inhalation composition comprises the following steps:
S1, conveying the 1% solid concentration budesonide ethanol solution through a first conveying component;
S2, conveying the ambroxol hydrochloride aqueous solution with the solid concentration of 1% through a second conveying component, and mixing the ambroxol hydrochloride aqueous solution and the budesonide ethanol solution to form a mixed solution;
and S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition.
The compound inhalation composition exists in the form of particles.
Wherein the conveying speed V1 of the first conveying component is 8ml/min, and the conveying speed V2 of the second conveying component is 2 ml/min;
The concentration C1 of the budesonide solution is 0.125g/ml, and the concentration C2 of the ambroxol hydrochloride solution is 0.500 g/ml.
the conveying speed of the third conveying component 103 is 160-330m3and the temperature of the conveyed drying gas is 60-100 ℃, and the drying rate of the drying gas conveyed by the third conveying part 103 for drying the budesonide ethanol solution and the ambroxol hydrochloride aqueous solution is 600L/h.
example 4
In one embodiment of the present invention, a method for preparing a compound inhalation composition comprises the following steps:
S1, conveying the 1% solid concentration budesonide ethanol solution through a first conveying component;
S2, conveying the ambroxol hydrochloride aqueous solution with the solid concentration of 1% through a second conveying component, and mixing the ambroxol hydrochloride aqueous solution and the budesonide ethanol solution to form a mixed solution;
And S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition.
the compound inhalation composition exists in the form of particles.
Wherein the conveying speed V1 of the first conveying component is 2ml/min, and the conveying speed V2 of the second conveying component is 8 ml/min;
The concentration C1 of the budesonide solution is 0.500g/ml, and the concentration C2 of the ambroxol hydrochloride solution is 0.125 g/ml.
The conveying speed of the third conveying component 103 is 160-330m3And the temperature of the conveyed drying gas is 60-100 ℃, and the drying rate of the drying gas conveyed by the third conveying part 103 for drying the budesonide ethanol solution and the ambroxol hydrochloride aqueous solution is 800L/h.
Example 5
In one embodiment of the present invention, a method for preparing a compound inhalation composition comprises the following steps:
S1, conveying the 1% solid concentration budesonide ethanol solution through a first conveying component;
s2, conveying the ambroxol hydrochloride aqueous solution with the solid concentration of 1% through a second conveying component, and mixing the ambroxol hydrochloride aqueous solution and the budesonide ethanol solution to form a mixed solution;
And S3, conveying the dry gas through a third conveying component, and drying the mixed solution to form the compound inhalation composition.
The compound inhalation composition exists in the form of particles.
Wherein the conveying speed V1 of the first conveying component is 1ml/min, and the conveying speed V2 of the second conveying component is 9 ml/min;
The concentration C1 of the budesonide solution is 1.000g/ml, and the concentration C2 of the ambroxol hydrochloride solution is 0.111 g/ml.
the conveying speed of the third conveying component 103 is 160-330m3And the temperature of the conveyed drying gas is 60-100 ℃, and the drying rate of the drying gas conveyed by the third conveying part 103 for drying the budesonide ethanol solution and the ambroxol hydrochloride aqueous solution is 1000L/h.
example 6
The compound inhalation compositions prepared in examples 2 to 5 were detected by X-ray photoelectron spectroscopy, and the results are shown in the following table, wherein the compositions are calculated by weight percent:
| Budesonide | ambroxol hydrochloride | |
| Example 2 | 95 | 5 |
| example 3 | 75 | 25 |
| Example 4 | 60 | 40 |
| Example 5 | 50 | 50 |
The compound inhalation compositions of examples 2 to 5 were respectively selected and respectively placed in simulated lung mucus at 50mg, and the respective dissolution curves are respectively shown in fig. 2 to 5.
As can be seen from the figure, in the compound inhalation composition of example 5, the two active ingredients can be dissolved out in equal proportion.
Example 7
This example is a pharmacodynamic test of examples 2 to 5.
firstly, a male New Zealand white rabbit pneumonia model is established, and the steps are as follows: an animal model is established by a percutaneous trachea puncture method, the trachea is exposed after an animal is anesthetized in the model, a micro-injector is used for absorbing a certain amount of bacteria liquid, the bacteria liquid is inserted between the cricoid cartilages and then injected, the animal stands upright, and the bacteria liquid uniformly reaches two lungs. After general anesthesia, male New Zealand white rabbits are inserted into the bronchus through a silicon tube, and the bacterial suspension is slowly injected. After the injection, the catheter is quickly pulled out, so that the rabbit keeps upright for 15s, and a rabbit lung chain pneumonia model is established.
Secondly, after the pneumonia model is established, the 28 male new zealand white rabbits which are successfully modeled are randomly divided into 7 groups, budesonide powder, ambroxol hydrochloride powder and the compound inhalation composition of the embodiment 2, the embodiment 3, the embodiment 4 and the embodiment 5 are sequentially led in from a silica gel catheter, and the last group is set as a blank control group.
The diagnostic criteria of the pneumonia model are provided by American ALYershov when studying the quantity of the streptococcus pneumoniae bacteria and whether the model building is successful, and include clinical diagnostic criteria, radiology criteria, laboratory criteria, microbiological criteria, visual criteria, 6-aspect specification of histological criteria (TABLE1 pneumonia diagnostic criteria) and macroscopic score for lung tissue (TABLE2 lung macroscopic score grid): normal, 0 point; scar, 1 point; mild hyperemia, 2 points; red congestion, 3 points; gray blood, 4 points; yellow congestion, 5 points.
Finally, the results of the seven groups are shown in the following table:
As can be seen from the above table, the compound inhalation composition of the present invention has good experimental results compared to the use of budesonide powder or ambroxol hydrochloride powder alone.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (10)
1. a method of preparing a compound inhalation composition comprising the steps of:
S1, conveying the budesonide solution through a first conveying component;
s2, conveying the ambroxol hydrochloride solution through a second conveying component, and mixing the ambroxol hydrochloride solution and the budesonide solution to form a mixed solution;
S3, conveying a drying gas through a third conveying component, and drying the mixed solution to form a compound inhalation composition;
Wherein the conveying speed of the first conveying component is V1, the conveying speed of the second conveying component is V2, and the units of V1 and V2 are ml/min;
The concentration of the budesonide solution is C1, the concentration of the ambroxol hydrochloride solution is C2, and the units of C1 and C2 are g/ml;
Wherein V1 is different from V2, and C1 is different from C2.
2. a method of preparing a combination inhalation composition according to claim 1, wherein the delivery velocity V1 of the first delivery member is greater than the delivery velocity V2 of the second delivery member;
The concentration C1 of the budesonide solution is less than the concentration C2 of the ambroxol hydrochloride solution.
3. a method of preparing a combination inhalation composition according to claim 1, wherein the delivery velocity V1 of the first delivery member is less than the delivery velocity V2 of the second delivery member;
the concentration C1 of the budesonide solution is greater than the concentration C2 of the ambroxol hydrochloride solution.
4. a process for the preparation of a combination inhalation composition according to any of claims 1 to 3, wherein the product of the delivery speed V1 of the first delivery means and the concentration C1 of the budesonide solution is V3, the product of the delivery speed V2 of the second delivery means and the concentration C2 of the ambroxol hydrochloride solution is V4, and the units of V3 and V4 are g/min;
wherein V3 is the same as V4.
5. The method of preparing a combination inhalation composition of claim 4, wherein V3 is 1 g/ml;
V4 was 1 g/ml.
6. The method for preparing a combination inhalation composition of claim 1, wherein the delivery speed of the third delivery member is 160-330m3/h。
7. A method of preparing a combination inhalation composition according to claim 1, wherein the temperature of the drying gas is 60-100 ℃.
8. A compound inhalation composition prepared by the preparation method of the compound inhalation composition as claimed in any one of claims 1 to 7, which is characterized by comprising budesonide and ambroxol hydrochloride.
9. The compound inhalation composition according to claim 8, wherein the weight percentage of budesonide is greater than the weight percentage of ambroxol hydrochloride; or
The weight percentage of the budesonide is equal to the weight percentage of the ambroxol hydrochloride; or
The weight percentage of the budesonide is less than that of the ambroxol hydrochloride.
10. The compound inhalation composition of claim 8, consisting of, in weight percent:
Budesonide 1-50%
50-99% of ambroxol hydrochloride;
Or
Budesonide 50-99%
1-50% of ambroxol hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910845879.2A CN110575446A (en) | 2019-09-09 | 2019-09-09 | compound inhalation composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910845879.2A CN110575446A (en) | 2019-09-09 | 2019-09-09 | compound inhalation composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110575446A true CN110575446A (en) | 2019-12-17 |
Family
ID=68812713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910845879.2A Pending CN110575446A (en) | 2019-09-09 | 2019-09-09 | compound inhalation composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110575446A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114027A (en) * | 2009-12-30 | 2011-07-06 | 李运智 | Oxygen-driven atomized inhalation solution for infant asthmatic suffocating pneumonia |
| EP2552414A1 (en) * | 2010-03-31 | 2013-02-06 | Glenmark Pharmaceuticals Limited | Pharmaceutical powder composition for inhalation |
| EP2898914A2 (en) * | 2007-07-06 | 2015-07-29 | Manta Devices, LLC | Inhalation devices for storing and delivering medicament |
| CN105250216A (en) * | 2015-09-28 | 2016-01-20 | 成都天台山制药有限公司 | Ambroxol hydrochloride injection suitable for aerosol inhalation |
| CN107669635A (en) * | 2016-09-30 | 2018-02-09 | 青岛大学 | It is a kind of to be used to treat aerosol of respiratory disease and preparation method thereof |
| CN109674847A (en) * | 2019-01-30 | 2019-04-26 | 山东省立医院 | A kind of atomization medicine composition and preparation method thereof for treating cough and asthma |
-
2019
- 2019-09-09 CN CN201910845879.2A patent/CN110575446A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2898914A2 (en) * | 2007-07-06 | 2015-07-29 | Manta Devices, LLC | Inhalation devices for storing and delivering medicament |
| CN102114027A (en) * | 2009-12-30 | 2011-07-06 | 李运智 | Oxygen-driven atomized inhalation solution for infant asthmatic suffocating pneumonia |
| EP2552414A1 (en) * | 2010-03-31 | 2013-02-06 | Glenmark Pharmaceuticals Limited | Pharmaceutical powder composition for inhalation |
| CN105250216A (en) * | 2015-09-28 | 2016-01-20 | 成都天台山制药有限公司 | Ambroxol hydrochloride injection suitable for aerosol inhalation |
| CN107669635A (en) * | 2016-09-30 | 2018-02-09 | 青岛大学 | It is a kind of to be used to treat aerosol of respiratory disease and preparation method thereof |
| CN109674847A (en) * | 2019-01-30 | 2019-04-26 | 山东省立医院 | A kind of atomization medicine composition and preparation method thereof for treating cough and asthma |
Non-Patent Citations (2)
| Title |
|---|
| 王彦: ""盐酸氨溴索与布地奈德联合雾化吸入治疗支气管肺炎164例疗效分析"", 《中国医药指南》 * |
| 王玉琢: ""氨溴索联合布地奈德治疗新生儿肺炎临床效果观察"", 《智慧健康》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110575446A (en) | compound inhalation composition and preparation method thereof | |
| Ozturk et al. | The use of dornase alpha for post-operative pulmonary atelectasis after congenital heart surgery | |
| CN110755413B (en) | Ambroxol hydrochloride solution for inhalation and preparation method thereof | |
| Robinson | Structure and function of the tracheobronchial system | |
| Marshall et al. | Gastric acid aspiration risk following cardiac surgery: 034 | |
| CN108997870A (en) | A kind of green inner wall purification coating and preparation method thereof | |
| Witkowska et al. | A new type of glycoconjugate vaccine containing Klebsiella fimbriae type 1 and 3 as carrier proteins | |
| Sorkine et al. | Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients | |
| Srámek et al. | Impact of CVVHD on pulmonary gas exchange measurement | |
| Kuhlen et al. | Fluctuations of inspiratory concentration of nitric oxide (NO) during mechanical ventilation | |
| Van Droogenbroeck et al. | Tau in serum and CSF during cerebral injury | |
| Staubach et al. | Induction of endotoxin (ET) tolerance by atoxic endotoxin-a new prophylactic concept to the septic syndrome | |
| Donati et al. | Predictive value of interleukin 6 (IL-6) and gastric intramucosal pH (pH-i) levels in splanchnic ischemia during major abdominal surgery | |
| Spies et al. | The urinary ratio of 5-hydroxytryptophol and 5-hydroxyindole-3-acetic acid in patients with chronic alcohol misuse | |
| Codazzi et al. | Outcome prediction in patients after out-of-hospital cardiac arrest cannot be improved by prolonging observation | |
| Factore et al. | Correlation between QT interval and serum level of calcium | |
| Afessa et al. | APACHE II score is better than weaning indices in predicting prolonged mechanical ventilator dependence | |
| Malbrain et al. | Validation of the esophageal detector device (EDD) in elective and emergency intubation in a medical ICU | |
| Gašparovic et al. | Biocompatible membranes in acute renal failure (ARF), hope or illusion? | |
| Schmidt et al. | Influence of dopexamine on leukocyte adherence and vascular permeability during endotoxemia in rat mesenteric venules | |
| Oldner et al. | Bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock | |
| Shvyrev et al. | Monitoring of electrical activity of small bowel in patients with generalized peritonitis | |
| Morgan et al. | A new algorithm for the determination of intramucosal pH and mucosal plasma lactate concentration | |
| Standl et al. | Peri-operative changes of haemodynamics and oxygen transport in patients undergoing haemodilution with bovine haemoglobin | |
| Lafuente et al. | Effects of the continuous venovenous haemofiltration, in the haemodynamic profile of shock septic patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191217 |
|
| RJ01 | Rejection of invention patent application after publication |